Press Releases for CEPH

Press Releases
Cephalon Completes Acquisition of Arana Therapeutics
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Cephalon Delivers Record Sales in the Second Quarter 2009 ; Sales and Adjusted Net Income Exceed Guidance; NUVIGIL Launch Off to Strong Start
Cephalon Delivers Record Sales in the Second Quarter 2009
Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Cephalon Quarterly Conference Call Invitation
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
Friday's News Makers - CarMax, Toyota, Cephalon, Harley Davidson, Electronic Arts; Research by InvestorSoup.com
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
Gabelli & Company, Inc.’s Healthcare Symposium
Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
Cephalon Announces Exercise of $65 Million Over-Allotment Option on 2.50% Convertible Senior Subordinated Notes - May 22 2009 12:55PM
Cephalon Announces Exercise of $65 Million Over-Allotment Option on 2.50% Convertible Senior Subordinated Notes - May 22 2009 9:55AM
Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
Alkermes Reports Financial Results for Fiscal 2009 and Provides Financial Expectations for Fiscal 2010
Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
Cephalon Acquires Controlling Interest in Arana Therapeutics
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Cephalon Reports Strong Sales and Earnings for the First Quarter 2009
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Cephalon Quarterly Conference Call Invitation - Mar 31 2009 2:33PM
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics - Feb 27 2009 8:22AM
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics - Feb 27 2009 1:14AM
Cephalon's New Product Launches Pace Record 2008 Sales
Zacks Analyst Blog Highlights: Alkermes, Cephalon, Drugstore.Com, Inc., Vivo ParticipaÃ§ÃµEs S.A. And Telemig
Cephalon Appoints Sarma P. Duddu As General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
Zacks Industry Rank Analysis Highlights: Cephalon, CONSOL Energy, Intel, Sunoco and Varian Medical Systems - Dec 26 2008 12:52AM
Zacks Analyst Blog Highlights: Unibanco Uniao De Bancos Brasileiros SA, Banco Itau Holding Financeira S.A., ADC Telecommunications, SAP AG and Cephalon Inc.
Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
Cephalon Added to S&P 500 Today
Standard & Poor's Announces Changes to U.S. Indices - 11-11-08
Gabelli & Company to Host Inaugural Best Ideas Conference - Nov 11 2008 9:01AM
Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. And GlaxoSmithKline Inc.
Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Cephalon, Inc. to Webcast Analyst Day
Cephalon Reports Another Strong Quarter
Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices
Cephalon Quarterly Conference Call Invitation - Sep 19 2008 9:21AM
Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
Analyst Reports for Shanda Interactive Entertainment Limited, Costco Wholesale Corporation, Cephalon Inc., And Zumiez Inc.
Zacks Analyst Blog Highlights: Comerica Inc., Advance Auto Parts, Inc., Eurand N.V., Cephalon Inc. And GlaxoSmithKline Plc.
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Zacks Bull and Bear of the Day Highlights: Canadian Solar, Corp. Executive Board, UDR, Cephalon and ASML Holding
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Cephalon Quarterly Conference Call Invitation - Jun 26 2008 10:37AM
Cephalon Announces Issuance of Patent for AMRIX
Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Wall Street Media Presents Three CEO Highlights from the 2008 FBR Capital Markets Conference
Stock on the Move for Thursday: TORO! May 8, 2008 - May 27 2008 12:49AM
Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA - Jun 1 2008 4:05PM
Cephalon Conference Call Invitation - Jun 1 2008 4:04PM
Cephalon Reports Strong First Quarter Earnings - Jun 1 2008 4:04PM
Cephalon Appoints Gerald J. Pappert as General Counsel
Cephalon Notified of Generic Fentanyl Buccal Tablet Filing
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Seven Summits Research Releases Comments on WMT, HAL, MS, ANF, and CEPH